Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

La Caixa launches $22m science seed fund

La Caixa launches $22m science seed fund

Mar 22, 2016 • Robert Lavine

The financial services provider will look to invest in seed-stage companies developing disruptive technologies with long development time frames.

Spain-based financial services firm La Caixa has launched a seed-stage venture capital fund called Caixa Innvierte Start that will be equipped with an initial €20m ($22m).

Caixa Innvierte Start will be overseen by La Caixa’s VC management firm, Caixa Capital Risc, but the initial capital could be topped up by external investments from the private or public sector.

The fund will target seed-stage companies working on disruptive scientific technologies that will need lengthy development before they get to market. Startups emerging from universities or research centres are expected to receive a substantial portion of the capital.

Caixa Innvierte Start will invest between $550,000 and $2.2m in each portfolio company, and is looking to partner investors that specialise in the sector.

The first company to receive cash through the initiative is Aelix, the Spain-based HIV immunotherapy developer that raised $12.7m in a January 2015 series A round featuring Caixa Capital Risc, healthcare group Johnson & Johnson and Ysios Capital.

Caixa Capital Risc currently has approximately $200m under management and a 175-strong portfolio spread across eight funds.

– This story first appeared in our sister publication Global Corporate Venturing.

The financial services provider will look to invest in seed-stage companies developing disruptive technologies with long development time frames.

Spain-based financial services firm La Caixa has launched a seed-stage venture capital fund called Caixa Innvierte Start that will be equipped with an initial €20m ($22m).

Caixa Innvierte Start will be overseen by La Caixa’s VC management firm, Caixa Capital Risc, but the initial capital could be topped up by external investments from the private or public sector.

The fund will target seed-stage companies working on disruptive scientific technologies that will need lengthy development before they get to market. Startups emerging from universities or research centres are expected to receive a substantial portion of the capital.

Caixa Innvierte Start will invest between $550,000 and $2.2m in each portfolio company, and is looking to partner investors that specialise in the sector.

The first company to receive cash through the initiative is Aelix, the Spain-based HIV immunotherapy developer that raised $12.7m in a January 2015 series A round featuring Caixa Capital Risc, healthcare group Johnson & Johnson and Ysios Capital.

Caixa Capital Risc currently has approximately $200m under management and a 175-strong portfolio spread across eight funds.

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here